Related Experiment Videos
Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures
Insights
Vancomycin hydrochloride did not significantly reduce shunt-associated infections in pediatric patients but caused adverse reactions like rash and hypotension, leading to study discontinuation.
Area of Science:
- Pediatric Surgery
- Infectious Diseases
- Pharmacology
Background:
- Central nervous system (CNS) shunt procedures are critical for managing hydrocephalus in children.
- Preventing shunt-associated infections is a major clinical challenge.
- Antibiotic prophylaxis is standard, but optimal agents and regimens require investigation.
Purpose of the Study:
- To evaluate the efficacy of vancomycin hydrochloride in preventing shunt-associated infections in pediatric patients undergoing CSF shunt procedures.
- To assess the safety and adverse reactions associated with vancomycin prophylaxis in this population.
Main Methods:
- A randomized, double-blind, controlled trial involving 37 pediatric patients in two countries.
- Participants received either vancomycin hydrochloride (15 mg/kg/dose) or placebo (saline) pre-operatively and six hours post-operatively.
- Shunt-associated infections and adverse events were monitored and recorded.
Main Results:
- Shunt-associated infections occurred in 17% of vancomycin recipients (3/18) and 23% of placebo recipients (4/17).
- All identified infections were caused by vancomycin-susceptible Staphylococcus species.
- A histaminelike rash developed in 35% of patients receiving vancomycin, with one case of associated hypotension.
Conclusions:
- Vancomycin hydrochloride did not demonstrate a significant reduction in shunt-associated infections compared to placebo in this study.
- The incidence of adverse reactions, particularly rash and potential hypotension, was notable with vancomycin prophylaxis.
- Due to adverse events, the study was discontinued, highlighting safety concerns with vancomycin in this setting.
Abstract:
From January to May 1982, 37 children undergoing CSF shunt procedures in two different countries were enrolled in a randomized, double-blind, controlled study to receive vancomycin hydrochloride (15 mg/kg/dose) or placebo (saline) one hour before surgery and again six hours later. Twenty patients received vancomycin, and 17 received placebo. In the 35 cases that could be evaluated, shunt-associated infections developed in three (17%) of 18 patients who received vancomycin and in four (23%) of the 17 placebo recipients. All infections were caused by Staphylococcus species susceptible to vancomycin. A histaminelike rash developed in seven (35%) of 20 patients during vancomycin infusion. It recurred with readministration in one patient and was accompanied by hypotension in another patient. The reactions were not related to too rapid infusion of vancomycin. Because of the adverse reactions to vancomycin, the study was discontinued.